Jul. 3 at 10:20 PM
$LRMR initiated coverage from HC Wainwright with a Buy rating and a
$10 price target, highlighting the long-term commercial potential of nomlabofusp.
The firm's outlook assumes a potential 2027 launch, with initial sales ramping from roughly
$48M and eventually exceeding
$1B in peak annual revenue if development and commercialization proceed successfully.
For investors, the opportunity is tied to execution. As with most clinical-stage biotech companies, valuation will depend on regulatory milestones, clinical data, and commercialization progress rather than long-term sales forecasts alone. If key catalysts are delivered, the market could begin pricing in a larger share of that future revenue potential.
